FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891269370> ?p ?o ?g. }

• W2891269370 endingPage "6333" @default.
• W2891269370 startingPage "6325" @default.
• W2891269370 abstract "Over the last decades, pertussis showed periodic increases in its incidence among adults, despite being a vaccine-preventable disease. This phase III, multicenter, extension study (NCT00489970) was conducted in adults from the United States, followed at Year (Y) 5 and Y9 post-vaccination with a dose of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine containing either 3 (Tdap-B group) or 5 pertussis components (Tdap-A group). Willing participants in Tdap groups and newly-recruited participants (Control group) received one Tdap-B dose at Y9. Antibody persistence (at Y5 and Y9) and safety of Tdap-B at Y9 were assessed. Non-inferiority of immune response elicited by 2 Tdap doses was evaluated at Y9: (i) versus one Tdap-B dose for diphtheria and tetanus in terms of seroprotection rates; (ii) for all antigens in terms of booster response rates (Tdap-B and Tdap-A groups versus Control group); and (iii) for pertussis antigens in terms of geometric mean concentrations (GMCs) versus a 3-dose series of a combined diphtheria-tetanus-acellular pertussis vaccine (DTPa) administered during infancy. 1257 participants were enrolled at Y5 and 809 participants were vaccinated at Y9. Seroprotection rates in both Tdap groups were ≥98.4% and ≥98.0% (Y5) and ≥98.3% and ≥98.1% (Y9) for diphtheria and tetanus, respectively. For pertussis antigens, antibody concentrations above assay cut-offs were observed for ≥76.6% (Y5) and ≥84.9% (Y9) of participants in Tdap groups. At Y9, one month post-Tdap vaccination, comparable seroprotection/seropositivity rates and antibody GMCs were observed among groups. Non-inferiority of immune responses in both Tdap groups was demonstrated when compared to the Control group for diphtheria and tetanus and to a 3-dose DTPa series for pertussis antigens. Non-inferiority criteria in terms of booster response were not met for all antigens. No safety concerns were raised. A second dose of Tdap-B administered in adults, 9 years after initial Tdap vaccination, is immunogenic and well-tolerated." @default.
• W2891269370 created "2018-09-27" @default.
• W2891269370 creator A5032510937 @default.
• W2891269370 creator A5037183731 @default.
• W2891269370 creator A5052717145 @default.
• W2891269370 creator A5073348371 @default.
• W2891269370 creator A5073592476 @default.
• W2891269370 date "2018-10-01" @default.
• W2891269370 modified "2023-09-27" @default.
• W2891269370 title "Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults" @default.
• W2891269370 cites W1893253902 @default.
• W2891269370 cites W1970924889 @default.
• W2891269370 cites W1987366134 @default.
• W2891269370 cites W1998845424 @default.
• W2891269370 cites W2010328305 @default.
• W2891269370 cites W2012925344 @default.
• W2891269370 cites W2013246812 @default.
• W2891269370 cites W2019415963 @default.
• W2891269370 cites W2027431547 @default.
• W2891269370 cites W2028507949 @default.
• W2891269370 cites W2052539517 @default.
• W2891269370 cites W2072437089 @default.
• W2891269370 cites W2097594720 @default.
• W2891269370 cites W2098217871 @default.
• W2891269370 cites W2099620118 @default.
• W2891269370 cites W2126068345 @default.
• W2891269370 cites W2131392937 @default.
• W2891269370 cites W2158985300 @default.
• W2891269370 cites W2272632494 @default.
• W2891269370 cites W2294639738 @default.
• W2891269370 cites W2341479591 @default.
• W2891269370 cites W2344927800 @default.
• W2891269370 cites W2561860321 @default.
• W2891269370 cites W2583780745 @default.
• W2891269370 cites W2793884390 @default.
• W2891269370 cites W2796104909 @default.
• W2891269370 cites W2797346081 @default.
• W2891269370 cites W4250229633 @default.
• W2891269370 doi "https://doi.org/10.1016/j.vaccine.2018.08.051" @default.
• W2891269370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30197282" @default.
• W2891269370 hasPublicationYear "2018" @default.
• W2891269370 type Work @default.
• W2891269370 sameAs 2891269370 @default.
• W2891269370 citedByCount "13" @default.
• W2891269370 countsByYear W28912693702018 @default.
• W2891269370 countsByYear W28912693702019 @default.
• W2891269370 countsByYear W28912693702020 @default.
• W2891269370 countsByYear W28912693702021 @default.
• W2891269370 countsByYear W28912693702022 @default.
• W2891269370 countsByYear W28912693702023 @default.
• W2891269370 crossrefType "journal-article" @default.
• W2891269370 hasAuthorship W2891269370A5032510937 @default.
• W2891269370 hasAuthorship W2891269370A5037183731 @default.
• W2891269370 hasAuthorship W2891269370A5052717145 @default.
• W2891269370 hasAuthorship W2891269370A5073348371 @default.
• W2891269370 hasAuthorship W2891269370A5073592476 @default.
• W2891269370 hasBestOaLocation W28912693701 @default.
• W2891269370 hasConcept C12590561 @default.
• W2891269370 hasConcept C147483822 @default.
• W2891269370 hasConcept C187212893 @default.
• W2891269370 hasConcept C203014093 @default.
• W2891269370 hasConcept C22070199 @default.
• W2891269370 hasConcept C2779841045 @default.
• W2891269370 hasConcept C2780572238 @default.
• W2891269370 hasConcept C2780801004 @default.
• W2891269370 hasConcept C2780868878 @default.
• W2891269370 hasConcept C71924100 @default.
• W2891269370 hasConceptScore W2891269370C12590561 @default.
• W2891269370 hasConceptScore W2891269370C147483822 @default.
• W2891269370 hasConceptScore W2891269370C187212893 @default.
• W2891269370 hasConceptScore W2891269370C203014093 @default.
• W2891269370 hasConceptScore W2891269370C22070199 @default.
• W2891269370 hasConceptScore W2891269370C2779841045 @default.
• W2891269370 hasConceptScore W2891269370C2780572238 @default.
• W2891269370 hasConceptScore W2891269370C2780801004 @default.
• W2891269370 hasConceptScore W2891269370C2780868878 @default.
• W2891269370 hasConceptScore W2891269370C71924100 @default.
• W2891269370 hasIssue "42" @default.
• W2891269370 hasLocation W28912693701 @default.
• W2891269370 hasLocation W28912693702 @default.
• W2891269370 hasOpenAccess W2891269370 @default.
• W2891269370 hasPrimaryLocation W28912693701 @default.
• W2891269370 hasRelatedWork W1999639125 @default.
• W2891269370 hasRelatedWork W2007936858 @default.
• W2891269370 hasRelatedWork W2012925344 @default.
• W2891269370 hasRelatedWork W2015712765 @default.
• W2891269370 hasRelatedWork W2028507949 @default.
• W2891269370 hasRelatedWork W2056999367 @default.
• W2891269370 hasRelatedWork W2085713763 @default.
• W2891269370 hasRelatedWork W2442763430 @default.
• W2891269370 hasRelatedWork W2513868392 @default.
• W2891269370 hasRelatedWork W3005979144 @default.
• W2891269370 hasVolume "36" @default.
• W2891269370 isParatext "false" @default.
• W2891269370 isRetracted "false" @default.
• W2891269370 magId "2891269370" @default.
• W2891269370 workType "article" @default.